Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001
Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications Interim safety and pharmacokinetic data from BBT002-01 study...
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide...
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials. In...